Partnership Opportunities With a small team and a focus on novel peptide therapeutics, Lytica Therapeutics may benefit from outsourced research and development collaborations to accelerate discovery, preclinical testing, and asset progression without expanding in-house headcount.

Manufacturing Access As a peptide-focused biotech, Lytica could require GMP-grade peptide synthesis, formulation development, and clinical-grade manufacturing capacity to move assets toward IND-enabling studies and trials.

Regulatory Support Given modest funding and revenue, Lytica may value outsourced CMC documentation, analytical method development, stability studies, and regulatory consulting to de-risk regulatory submissions and extend cash runway.

Funding Strategy With 5.3M in funding, explore co-development deals with larger biopharma or non-dilutive grants to extend runway and unlock access to capital for later-stage development.

Ecosystem Advantage Based in Boston, Lytica sits in a dense biotech ecosystem; capitalize on local CROs, academic partnerships, and biopharma networks to source collaborations, testing services, and early-stage partnering opportunities.